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Irinotecan, mitomycin and cisplatin all demonstrate activity in gastro-oesophageal cancers. This novel combination was
administered to outpatients with previously untreated inoperable gastro-oesophageal or pancreatic cancer, in a 28-day cycle. A
total of 26 out of 31 patients with gastro-oesophageal cancer and 12 out of 14 patients with pancreatic cancer have been
treated with this combination, and were evaluable for response. The overall response rates for patients with gastro-
oesophageal cancer was 42%, with a median survival of 9.5 months. In patients with pancreatic cancer, the overall response
rate was 42% with a median survival of 8 months. There was a statistically signiﬁcant increase in survival between those
patients who achieved a stable disease response and those who achieved either a partial response or complete response. The
toxicity proﬁles for both cancers were virtually identical. There were ﬁve treatment-related deaths, and a high admission rate
(42%). Thus irinotecan, mitomycin and cisplatin is a new combination with activity in inoperable upper gastro-oesophageal
cancers, but with a high toxicity proﬁle. Future developments include reducing the dose of irinotecan and number of cycles of
therapy to four.
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The treatment for inoperable upper gastro-intestinal malignancies
remains unsatisfactory. Single agent treatment with 5-ﬂuorouracil
(5FU), anthracyclines or cisplatin render response rates as low as
20% (Douglass, 1985). Combination therapies initially experienced
greater success: the original response rate for the standard treat-
ment in Europe, FAMTX (5FU, doxorubicin and methotrexate)
was 58% (Klein, 1989). Unfortunately a recent EORTC (European
Organisation for Research And Treatment of Cancer) study
comparing this regimen to ELF (bolus 5FU, etoposide and folinic
acid) and FUP (5FU and cisplatin) reported a dismal response
rate of 12% for the former, due at least in part to dose reductions
and treatment delays (Vanhoefer et al, 2000). There were no
signiﬁcant differences in response rates, toxicity proﬁles or overall
survival.
The current standard therapy in the United Kingdom for
patients with gastro-oesophageal cancer, adequate renal function
and a reasonable performance status is ECF (epirubicin, cisplatin
and continuous infusional ﬂuorouracil), the best results being
noted in patients with nodal and hepatic metastases (Webb et al,
1997). A randomised trial comparing ECF to FAMTX in patients
with advanced oesophagogastric cancer, reported response rates
of 45% and 21% respectively, with an increase in the median survi-
val duration from 5.7 to 8.9 months. The ECF regimen also
demonstrated better quality of life and less haematological toxicity,
compared to FAMTX. The regimen has, however, signiﬁcant inher-
ent problems: it has a moderately emetic potential, most patients
require overnight admission for the cisplatin administration, and
a tunnelled venous line is required for the delivery of 5FU. Hair
loss is common and problems related to the central line are not
infrequent. In addition, the infusional ﬂuorouracil requires a pump
change weekly either at hospital or at home by a district nurse.
Alternative regimens are thus being explored: the combination
of irinotecan with cisplatin has been attempted by several groups
in gastro-oesophageal cancer. In the initial study by Shirao et al
(1997), cisplatin 80 mg m
72 was given on day 1 and irinotecan
80 mg m
72 on days 1 and 15, the cycle being repeated every 28
days. Mild diarrhoea was seen in 47% of patients (grade 1+2),
which resolved with loperamide: only 4% had severe diarrhoea.
Nausea and vomiting were easily controlled with 5HT3 antagonists.
The response rate in this study was 42% with a median time to
response of 36 days. Boku et al (1999) used a similar 2-weekly
combination in patients with advanced gastric cancer. The overall
response rate was 48% in the 44 patients treated, with a median
survival of 272 days.
The drug mitomycin C has also been extensively investigated in
the treatment of upper gastro-intestinal cancers, as a single agent
or in combination, and in both adjuvant and metastatic settings.
In the 1970s, the FAM regimen comprising 5FU, doxorubicin,
mitomycin reported a response rate of 42% in patients with
advanced gastric cancer (Macdonald et al, 1980). More recently,
the results of the study comparing ECF and MCF (mitomycin,
cisplatin, 5FU) demonstrated identical response rates, disease-free
survival and overall survival (Andersen et al, 1999). Mitomycin is
a potential candidate for a combination chemotherapy regimen
in gastro-oesophageal cancer.
The aim of this study was to develop a regimen of these three
active drugs (irinotecan, cisplatin and mitomycin), in gastro-
oesophageal and pancreatic cancers, delivering it in a more
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city proﬁle and response rate.
MATERIALS AND METHODS
Patients were entered into the study following referral to the
Department of Medical Oncology, St. Bartholomew’s Hospital,
London, and if they satisﬁed the following entry criteria: histologi-
cally proven, inoperable adenocarcinoma or squamous carcinoma
of the oesophagus, adenocarcinoma of the stomach or pancreatic
carcinoma and had received no prior chemotherapy; performance
status 0–3; creatinine clearance or EDTA clearance greater than
50 ml min
71; adequate haematological reserve (i.e. platelets
4100610
9 l
71, white cell count 43610
9 l
71, haemoglobin
4100 g l
71 (may be transfused). The study had the approval of
the local research and ethics committee and patients were required
to give written informed consent.
All patients had baseline blood investigations and a staging CT
scan of the chest and abdomen, prior to the initiation of therapy.
Treatment
The combination regimen adopted by Boku et al (1999) used a
combination of 70 mg m
72 of irinotecan on days 1 and 15 with
80 mg m
72 of cisplatin on day 1 every 4 weeks, with acceptable toxi-
city proﬁles. We proposed to maintain a 2-weekly regimen, and thus
6m gm
72 of mitomycin was administered on Day 1 only, with
100 mg m
72 of irinotecan and 40 mg m
72 of cisplatin on Days 1
and 15 of the 28 day cycle. A total of 6 cycles of chemotherapy
were planned, with omission of mitomycin for the last 2 cycles.
Patients received oral pre-medication with granisetron 1 mg,
dexamethasone 16 mg and frusemide 40 mg. This was followed
by a 1 l infusion of normal saline with 10 mmol of potassium
and 10 mmols of magnesium sulphate over 1 h. Atropine was
administered if required. Irinotecan was administered over
30 min, cisplatin in 1 l of normal saline over 1 h.
Patients were reassessed using CT scanning after three cycles,
and if progressive disease identiﬁed, they were withdrawn from
the study. After six cycles, patients were again scanned.
Dose modiﬁcations
Prior to each chemotherapy cycle, the minimum platelet count and
neutrophil count permitted to receive treatment were 100610
9 l
71
and 1.0610
9 l
71, respectively. If these counts were not achieved,
treatment was delayed 1 week. If after 1 week’s delay, the platelet
count was greater than 75 and rising, and if the neutrophil count
was greater than 1610
9 l
71, the full dose of treatment was admi-
nistered. If the platelet count was less than 75, mitomycin was
prescribed at 50% of the original dose. If the platelet count was
between 30–75, a further 1 week’s delay was made, followed by
a 50% dose reduction in the mitomycin on all following cycles.
If the platelet count was less than 30, after the initial 1 week’s
delay, mitomycin was omitted on all subsequent courses, and all
other drugs reduced by 20%. If patients were admitted with Grade
3–4 infections, the doses of all drugs were reduced by 20% for
future cycles. If the creatinine increased by more than 15%, a crea-
tinine clearance was calculated. If this proved to be less than
40 ml min
71, cisplatin was omitted from subsequent courses.
Assessment of response
Responses to treatment were deﬁned according to World Health
Organisation (WHO) criteria. Patients were then seen regularly
in clinic. Survival from the date of treatment was analysed. Perfor-
mance status (PS) was also recorded, according again to the WHO
criteria.
Patient characteristics
From January, 1999 to March, 2001, 31 patients with previously
untreated inoperable gastro-oesphageal cancer and 14 patients with
pancreatic cancer were entered into the study. Their characteristics
are summarised in Table 1a and b. The PS was not documented in
four patients.
RESULTS
Twenty-six out of 31 patients with gastro-oesophageal cancer and
12 out of 14 patients with pancreatic cancer were evaluable for
response. The results are shown in Table 2a and b. The median
number of cycles administered in gastro-oesophageal and
pancreatic cancer patients was 2.5 and 2.25, respectively (range
0.5–6).
All the data was analysed on an intention to treat basis.
Gastro-oesophageal cancer
Complete remission was achieved in one patient, who had adenocar-
cinoma of the oesophagus and metastases to the coeliac lymph nodes
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Table 1
(a) Gastro-oesophageal cancer
Number 31
Male:Female 24:7
Median age in years 62 (Range 35–78)
PS:
11 2
21 4
31
Histology:
Adenocarcinoma 27
Squamous cell 3
Mixed 1
Extent:
Metastatic 28
Locally advanced 3
Sites of metastases
Bowel 3
Lung 5
Liver 12
Lymph nodes 22
Bone 1
Ascites 1
Intrathoracic 1
Spleen 1
Adrenal 1
(b) Pancreatic cancer
Number 14
Male:Female 9:5
Median age in years 62 (Range 48–76)
PS:
01
17
26
Histology:
Adenocarcinoma 14
Extent:
Metastatic 12
Locally advanced 2
Sites of metastasis
Liver 11
Ascites 2
Gallbladder 1
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oesophageal cancer, nine were in patients with metastatic disease.
Response rates relative to disease site gave the following results:
in the two patients with nodal disease, complete response (CR) was
achieved in one, stable disease (SD) in the other. In the 10 patients
with hepatic disease, partial response (PR) was documented in ﬁve,
SD in three, and progressive disease (PD) in two.
A PR response was reported in two out of the three patients
with peritoneal involvement, with PD being noted in the third.
Four out of the six patients with gastro-oesophageal cancer
stable disease after IPM, and seven out of the nine in whom a
response to IPM had been achieved, were progression free at 6
months.
Response according to performance status was also analysed. Four
out of the twelve patients with PS 1 achieved either a PR or CR
response, compared with 6 out of 9 patients with PS of 2–3.
Pancreatic cancer
CR was achieved in one patient with cancer of the pancreatic
head and liver metastases. None of the three patients with
pancreatic cancer that was stable after IPM, had progression-free
disease by 6 months, compared to four out of the ﬁve who
responded to IPM.
In pancreatic cancer, responses were noted in four out of the
seven patients with PS 0–1, and in one out of the three patients
with PS 2–3.
Non-evaluable patients
In total, the responses to IPM were not evaluable in seven patients
– ﬁve with gastro-oesophageal and two with pancreatic cancer. All
these patients had met the study entry criteria. The median PS of
the non-evaluable patients was 2.
Of these seven patients, one completed two cycles of IPM, but
did not attend further appointments at this Hospital, and died
on day 130 of an unknown cause. Six patients withdrew after
receiving day 1 of the ﬁrst cycle of IPM, four because of toxicity.
Toxicity data
Data on at least 125 courses of IPM was available for toxicity
assessment, and is shown in Table 3a and b. Twenty-six patients
had no admissions, 13 patients had one admission, four had two
admissions, and two patients had three admissions.
Overall the dose intensity of the IPM regimen was 97.2% (96.9%
for irinotecan and cisplatin and 97.7% for mitomycin).
DISCUSSION
The results of this preliminary study have demonstrated that the
combination of irinotecan, mitomycin and cisplatin (IPM)
produces an encouraging overall response rate of 42% and a
median survival of 9.5 months in patients with inoperable
gastro-oesophageal cancer. The response rate compares favourably
with the reported response rate of 45% in the multi-centre trial
of ECF (Webb et al, 1997). In contrast to ECF where a higher
response rate was noted in patients with nodal disease, no differ-
ence in the response rate to IPM was noted between patients
with lymph node, hepatic or peritoneal metastases. Six out of nine
patients with PS of 2–3 responded to IPM, leading to the observa-
tion that a poor initial performance state should not deter
enrolling such patients in studies.
In pancreatic cancer, the National Institute for Clinical Excel-
lence (NICE) has recommended considering single agent
gemcitabine as ﬁrst line therapy with a reported median survival
of 5.6 months (Burris et al, 1997). In the limited cohort of 14
patients with inoperable pancreatic cancer, the response rate to
IPM was 42%, with a median survival of 8 months. IPM has thus
shown promise, comparing favourably with the PEF-G regimen
(cisplatin, epirubicin, gemcitabine and continuous infusional
5FU), with its objective response rate of 58% in 43 patients (Reni
et al, 2001). The number of patients treated in this study, however,
is low, and would appear to reﬂect the poor referral rate to medical
oncologists and the general pessimism with which chemotherapy is
viewed in pancreatic cancer.
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Table 2 Response to IPM
(a) Response to IPM–gastro-oesophageal cancer
Response:
CR 1
PR 10
SD 8
PD 4
NE 5
TRD 3
Overall response rate 42%
(b) Response to IPM–pancreatic cancer
Response:
CR 1
PR 4
SD 3
PD 1
Marker response 1
NE 2
TRD 2
Overall response rate 42%
Table 3 Type of toxicity
Type of toxicity Cycles Gr0
a Gr1 Gr2 Gr3 Gr4 % Gr3/Gr4
(a) Toxicity data by cycle
Infection 130 102 8 10 10 0 8
Malaise 130 14 50 46 19 1 15
Nausea 128 52 52 20 4 0 3
Vomiting 129 84 18 24 3 2 4
Diarrhoea 131 76 36 14 3 2 4
Stomatitis 128 85 32 11 0 0 0
Anorexia 127 53 44 26 4 0 3
Alopecia 127 28 51 48 0 0 0
Neuro-sensory 127 106 18 3 0 0 0
Pain 129 59 55 13 2 0 2
Neutropenia 141 58 24 19 21 19 28
Thrombocytopenia 140 108 15 7 9 1 7
Renal toxicity 127 126 0 1 0 0 0
(b) Toxicity by patient
Infection 38 20 4 5 9 0 24
Malaise 38 0 6 17 14 1 40
Nausea 38 4 14 16 4 0 11
Vomiting 38 16 4 15 3 0 8
Diarrhoea 39 13 11 10 3 2 13
Stomatitis 38 18 11 9 0 0 0
Anorexia 38 2 12 20 4 0 11
Alopecia 37 2 13 22 0 0 0
Dyspnoea 37 24 4 8 1 0 3
Neuro-sensory 38 24 12 2 0 0 0
Neutropenia 39 3 8 8 10 10 51
Thrombocytopenia 39 20 9 3 6 1 18
Renal toxicity 37 36 0 1 0 0 0
aGr=Grade
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c.i. 6.7, 15.2: range 5.3–17.6 months) for patients with gastro-
oesophageal cancer, and 13.8 months (95% c.i. 2.9, 24.7: range
8–32.6 months) in patients with pancreatic cancer, compared with
median survival in the non- responders of 9.5 months (95% c.i.
1.7, 17.2: range 2.2–19.7 months) and 5.4 months (95% c.i. 2.0,
8.8: 1.0–7.3 months) respectively. Thus in patients with pancreatic
cancer, those who responded to IPM had a signiﬁcantly better
survival than those who did not (P=0.0018).
The median survival in the evaluable (n=26) vs the non-evaluable
(n=5) patients with gastro-oesophageal cancer was also found to be
statistically different: 10 months vs 2.3 months (P50.001).
The results in overall responders versus non-responders and
evaluable vs non-evaluable patients were, however, hampered by
the limited numbers of patients recruited thus far: there were only
two non-evaluable patients with pancreatic cancer. The data is
worthy of consideration, but must be viewed with caution.
Performance status did not appear to inﬂuence outcome to ther-
apy: in patients with both gastro-oesophageal and pancreatic
cancers, there was no statistical signiﬁcant difference in the median
survival, relative to the PS.
The IPM regimen had moderate toxicity, with the main side
effect being myelosuppression. There were no cases of nephrotoxi-
city with this regimen, despite concerns over the day case
administration of cisplatin with limited intravenous hydration.
However, there were ﬁve treatment-related deaths: three from
sepsis, one from multi-organ failure, and one from bowel perfora-
tion. In total, there were 27 inpatient episodes involving 19
patients: 12 inpatient admissions for infections, seven of these in
the presence of neutropenia. There were four admissions for
vomiting, three in the same patient. Two admissions were for
general malaise, one for a deep vein thrombosis, one for gastro-
intestinal bleed in the presence of a normal blood count and clot-
ting, and ﬁve admissions in two patients for undocumented
reasons. Two patients were admitted in order to administer
chemotherapy. Eleven of the original 45 patients failed to complete
the ﬁrst two cycles of IPM, because of toxicity (24%).
There was also a high rate of non-evaluable patients (7 out of
45: 16%). As has been noted the median performance status in this
group was 2, and the high drop-off rate may reﬂect the poor
general health in these patients.
Preclinical trials in gastric cancer combining mitomycin and
irinotecan suggested synergism. On the basis of this, a trial using
5m gm
72 of mitomycin and 100–150 mg m
72 of irinotecan every
2 weeks was initiated, and preliminary results demonstrated a
response in 5 out of 10 patients (Handa et al, 1999). The current
treatment scheduling of IPM has thus been fortuitous: recently
presented phase 1 data on irinotecan and mitomycin shows that a
modulatory/synergistic relationship may exist between these two
drugs, with mitomycin inducing topo-isomerase 1 gene expression
(Villalona-Calero et al, 2001). A number of trials have conﬁrmed
the role of irinotecan and cisplatin in the treatment of previously
untreated patients with metastatic adenocarcinoma of the oesopha-
gus and stomach, with reported response rates of 53% and 57%,
respectively (Ilson et al, 1999). Thus the pharmacological basis for
this trial appears sound.
This study has demonstrated the efﬁcacy and potential of IPM, a
non-ﬂuorouracil-based treatment, in upper gastro-oesophageal and
pancreatic cancers. Patients with pancreas cancer had a signiﬁcant
improvement in the median survival if a response to IPM was
achieved. The treatment has, however, resulted in a high toxicity
rate: a treatment-related death rate of 11%, and an admission rate
of 42%. Future adaptations to this regimen should take into
account the difﬁculties experienced, and reduce the dose of irino-
tecan to 70 mg m
72, and limit the number of cycles to four. Other
considerations should also be into exploring the addition of 5FU in
this regimen. To maintain the important outpatient element, 5FU
could be administered in its oral format, capecitabine.
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